Maternal serum perlecan levels in women with preeclampsia
| dc.contributor.author | Akbas, M | |
| dc.contributor.author | Koyuncu, FM | |
| dc.contributor.author | Artunc-Ulkumen, B | |
| dc.contributor.author | Taneli, F | |
| dc.contributor.author | Ozdemir, H | |
| dc.date.accessioned | 2025-04-10T10:26:47Z | |
| dc.date.available | 2025-04-10T10:26:47Z | |
| dc.description.abstract | Objective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perlecan levels were significantly higher (p = 0.016) in preeclamptic women with severe features(n = 23) than preeclampsia patients(n = 27). There were no statistically significant differences in serum perlecan levels between the early-onset preeclampsia(n = 25), late-onset preeclampsia(n = 25), and healthy pregnancies. Conclusion: Our findings suggest that preeclamptic women with severe features have higher serum perlecan levels than women with preeclampsia. | |
| dc.identifier.e-issn | 1525-6065 | |
| dc.identifier.issn | 1064-1955 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/34406 | |
| dc.language.iso | English | |
| dc.title | Maternal serum perlecan levels in women with preeclampsia | |
| dc.type | Article |